

Cadila Pharmaceuticals introduces quadrivalent influenza vaccine

04 March 2024 | News

Cadiflu Tetra Vaccine targets four strains of the Influenza virus subtype–A and B

Ahmedabad-based Cadila Pharmaceuticals has announced the launch of Cadiflu Tetra Vaccine, an advanced Quadrivalent Influenza Vaccine to prevent influenza, a recurrent, widespread and debilitating viral infection. The vaccine is approved by Drugs Controller General of India (DCGI) for use in adults and children.

Cadiflu Tetra Vaccine targets four strains of the Influenza virus subtype–A and B, responsible for seasonal epidemics. Developed using cutting-edge proprietary technology employing nano-sized particles, the vaccine mimics the external structure of the virus without containing intact genetic material.

The vaccine carries hemagglutinin (HA), neuraminidase (NA) and matrix 1 (M1) proteins from the respective strains aggregated together in a single formulation. The VLP vaccine replicates external structure of the viruses but does not contain any live genetic substance, which can cause viral replication and infection. Therefore, this vaccine is qualitatively superior and has better safety profile.

The Cadiflu Tetra Vaccine aims to reduce the incidence of influenza illness, mitigate the severity of the disease in affected individuals, and decrease the transmission of the infection to others. This breakthrough in vaccine development also holds promise for enhancing the protection of pregnant women against influenza, contributing to the overall well-being of both mother and child.